Table 1.

Demographics of subjects used in this study.

Subjects	Gender	Age (years)	HCV genotype	HCV quantification (IU/ml)	Anti-HCV antibody†
C1	Female	33	1a	0.2 × 105	N/A
C2	Female	59	1a	20 × 105	N/A
C3	Female	61	1a	1.2 × 105	N/A
C4	Female	54	1a	20 × 105	N/A
C5	Male	56	1a	1.7 × 105	N/A
C6	Female	59	1a	10 × 105	N/A
C7	Male	56	1a	0.6 × 105	N/A
C8	Female	61	1a	10 × 105	N/A
R9	Male	56	N/A	BLD	Positive
R10	Male	53	N/A	BLD	Positive
R11	Female	31	N/A	BLD	Positive
R12	Male	64	N/A	BLD	Positive
R13	Male	57	N/A	BLD	Positive
R14	Female	41	N/A	BLD	Positive
R15	Male	50	N/A	BLD	Positive
R16	Male	40	N/A	BLD	Positive
H17	Female	N/A	N/A	BLD	Negative
H18	Female	N/A	N/A	BLD	Negative
H19	Male	N/A	N/A	BLD	Negative
H20	Male	N/A	N/A	BLD	Negative

^†All subjects’ sera were screened for HCV antibodies, except for patients that had HCV RNA detectable by RT-PCR, as described in the ‘Patients, materials and methods’ section.

BLD: Below level of detection; C: Chronic; H: Healthy; IU: Infectious unit; N/A: Not assessed; R: Resolved.